Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder Clinical research trials and A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder. A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder clinical trial. Participants typically obtain the most effective healthcare available for their A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder



A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

For Condition: Bladder Neoplasms,Carcinoma, Transitional Cell
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
Details: Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
Eligibility:
Study Type:  Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: Histologically confirmed superficial transitional cell carcinoma of the bladder pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required. No metastatic disease or muscle invasion. Clinically useful pretreatment bladder function required. No significant prostatic obstructive symptoms associated with impaired or incomplete bladder emptying. No active urinary tract infection. PRIOR/CONCURRENT THERAPY: At least 1 course of prior standard intravesical therapy required. At least 4 weeks since intravesical treatment, with resolution of any local or systemic toxicity. PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: ECOG 0 or 1. Hematopoietic: WBC at least 3,300; Hemoglobin at least 10 g/dL. Hepatic: Bilirubin no greater than 1.5 mg/dL; AST and ALT no greater than 2 times normal. Renal: Creatinine no greater than 1.5 mg/dL. OTHER: Medically able to undergo cystoscopy. No pregnant women.
Total Enrollment: 18

Location and Contact Information:

National Cancer Institute (NCI)
Bethesda,  Maryland,  20892
United States
 


Additional Information:
Study ID Numbers:  940098;  94-C-0098
Study Start Date: March 2, 1994
Record last reviewed: January 1, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001381

Other Bladder Neoplasms Studies:
1. A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

2. Safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies.

3. TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium

Related Studies:

Other Bladder Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Modify your Search

  Other Bladder Neoplasms Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103